A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/RefractoryIndolent Lymphoma.
Type of Study: Clinical Trial
Sponsor / Support: Celgene
Primary Objectives: To evaluate the efficacy and safety of rituximab plus lenalidomide combination therapy insubjects with relapsed/refractoryindolent lymphoma
Design: This Phase 3 multicenter, double-blind, randomized study is designed to evaluate the efficacy and safety of rituximab plus lenalidomide versus rituximab plus placebo.
Sample Size: 350 patients
Principal Investigator: Phillip Scheinberg
Countries LATAM: Brazil
Ongoing studies
Breast
GBECAM 0115 – AMAZONA III
LACOG 0413 – Male Breast Cancer
LACOG 0419 – NEOSAMBA
LACOG 0615 – LATINABreast
LACOG 0715 – PALLAS
LACOG 2118 – ALEXANDRA/IMpassion 030
Gastrointestinal
LACOG/GTG 1318 – CCA
LACOG 0119
Gynecological
LACOG 0215 – EVITA
LACOG 0920 – Senticol III
LACOG 1018 – PALBO in Ovarian Cancer
Genitourinary
LACOG 0217 – IRONMAN
LACOG 0218 – Hercules
LACOG 0415 – APA in Prostate Cancer
LACOG 0515 – Testicular Registry
LACOG 0519 – PEACE III
LACOG 0620 – ExBAT
LACOG 1518 – Bladder Cancer Registry
LACOG 1818 – Prostate Cancer Registry
Head and Neck
LACOG 0318 – Induction
LACOG 0319
Lung
LACOG 0116 – LATINO LUNG
LACOG 0118 – RELANCE
LACOG 0417 – CNS MTX
LACOG 0618
LACOG 0718 – PCI Project
LACOG 1918
LACOG 2218 – PACIFIC BRAZIL
Neuro
LACOG 0619